Loading…
Invigorate Med Spa was cited for unlawfully selling unapproved and misbranded compounded drugs, specifically semaglutide and tirzepatide products, through its website to U.S. consumers. The company violated the Federal Food, Drug, and Cosmetic Act by making false or misleading claims that equated its compounded products to FDA-approved drugs (Wegovy and Mounjaro), when compounded drugs are not FDA-approved and cannot be marketed as equivalent to approved medications. These violations constituted misbranding under sections 502(a) and 502(bb) of the FDCA and prohibited introduction of adulterated products into interstate commerce under section 301(a).